

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

022460Orig1s000

Trade Name: Jalyn

Generic Name: Dutasteride 0.5 mg/Tamsulosin hydrochloride 0.4 mg

Sponsor: GlaxoSmithKline LLC
Research Triangle Park, NC 27709

Approval Date: June 14, 2010

Indications: Jalyn, a combination of dutasteride, a 5 α -reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
022460Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	X
Medical Review(s)	X
Chemistry Review(s)	X
Environmental Assessment	
Pharmacology Review(s)	X
Statistical Review(s)	X
Microbiology Review(s)	X
Clinical Pharmacology/Biopharmaceutics Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
022460Orig1s000

APPROVAL LETTER



NDA 022460

NDA APPROVAL

GlaxoSmithKline LLC
Attention: Sherman N. Alfors
Director, Antiviral/Antibacterial U.S. Regulatory Affairs
5 Moore Drive
Research Triangle Park, NC 27709

Dear Mr. Alfors:

Please refer to your New Drug Application (NDA) dated and received March 20, 2009, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Jalyn™ (dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg).

We acknowledge receipt of your submissions dated April 14, May 7, May 20, May 28, June 7, June 8, June 10, June 11, and June 14, 2010.

The April 14, 2010, submission constituted a complete response to our January 20, 2010, action letter.

This new drug application provides for the use of Jalyn™ (dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg) for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling text for the package insert and text for the patient package insert. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)”. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 022460.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable. BPH does not exist in children and recruiting children with BPH for a pediatric study would be impossible.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Olga Salis, Regulatory Project Manager, at (301) 796-0837.

Sincerely,

{See appended electronic signature page}

George Benson, M.D.
Deputy Director
Division of Reproductive and Urologic
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling (PI and PPI)
Carton and Container Labels

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22460	ORIG-1	SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLIN E	DUTASTERIDE/ TAMSULOSIN HYDROCHLORIDE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GEORGE S BENSON
06/14/2010